How does bedinvetmab work and what does the clinical evidence show for pain control in osteoarthritic dogs?

Question

Accepted Answer

Bedinvetmab (Librela) is a fully canine recombinant monoclonal antibody that binds nerve growth factor (NGF), preventing NGF from engaging its TrkA and p75 neurotrophin receptor (p75NTR) receptors and thereby reducing peripheral sensitization and pain signaling in osteoarthritic joints. NGF is elevated in the osteoarthritic joints of dogs and, following noxious stimulation, drives peripheral sensitization, neurogenic inflammation, and recruitment of additional proinflammatory mediators through TrkA signaling on peripheral nerves, immune cells, endothelial cells, synoviocytes, and chondrocytes. 2 Bedinvetmab selectively binds NGF without cross-reacting with neurotrophin-3, neurotrophin-4, or brain-derived neurotrophic factor. 2 The approved dose is 0.5–1.0 mg/kg SC once monthly, with effectiveness established after a minimum of two doses administered one month apart. 23 After the first dose, bedinvetmab has a mean half-life of 19.1 days (SD 8.3 days). 3 Efficacy data from two pivotal placebo-controlled field studies are consistent. In the EU registration study, treatment success on the Canine Brief Pain Inventory (CBPI) at Day 28 was 43.5% for bedinvetmab versus 16.9% for placebo. 1 Success rates continued to rise with repeated monthly dosing, reaching 50.8% at Day 56 and 48.2% at Day 84 in the bedinvetmab group, while the placebo group remained below 25% at all time points. 1 In the US registration study, Day 28 CBPI treatment success was 47.4% for bedinvetmab versus 36.6% for placebo, with a number needed to treat of 9.3 at Day 28 improving to 4.3 by Day 84 with continued monthly dosing. 3 Bedinvetmab produced significant improvement over placebo on all three CBPI components — pain interference score, pain severity score, and quality of life — in both studies. 13 Bedinvetmab is non-inferior to grapiprant by objective force plate gait analysis. CBPI treatment success at Day 42 was 68.8% for bedinvetmab and 56.3% for grapiprant, with the upper bound of the 90% confid